Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(4):342-353
Invasive mycoses becoming more and more important problem of the modern medicine that is reflecting the increasing number of immunocompromised patients population. Despite the fact that the main causative agents remain Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans, the number of cases of systemic fungal infection due to rare molds and nonalbicans strains of Candida spp. is increasing. Changes in the spectrum of causative agents and unacceptable high number of adverse events during the therapy with many of the traditional systemic antifungals leads to the necessity of creating new antifungal agents by widening of existing classes and by making new ones. In this article an attempt to describe the main representatives of the new antifungals and comparative analysis including pharmacokinetic, spectrum of activity, adverse events and the perspectives of their usage is made.